We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Delays Gilead’s Truvada sNDA for HIV Prevention Until Sept. 14
FDA Delays Gilead’s Truvada sNDA for HIV Prevention Until Sept. 14
June 15, 2012
The FDA has informed Gilead Sciences it needs at least three more months to weigh its Truvada sNDA for HIV prevention, AIDS advocates say.